BioSpace News Archive

ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported financial results and operational updates for the quarter ended June 30, 2023.

Addex Therapeutics reported its half-year and second quarter financial results for the periods ended June 30, 2023 and provided a corporate update.

Sosei Group Corporation and Cancer Research UK announce that the first patient has been dosed in a Phase I/IIa clinical trial evaluating Sosei Heptares’ orally available small molecule cancer immunotherapy drug HTL0039732 for advanced solid tumors.

Corium, LLC and Lotus Pharmaceutical announced that the companies have entered into an exclusive Collaboration and License Agreement for ADLARITY®, an innovative Alzheimer’s dementia treatment, in ten markets across Asia.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. FDA has granted accelerated approval of TALVEY™, a first-in-class bispecific antibody for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.

MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, announced its financial results for the second quarter of 2023.

Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, reported financial results for the second quarter ended June 30, 2023, and provided a business update.

Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fiscal first quarter ended June 30, 2023.

Virios Therapeutics, Inc. today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.

HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the second quarter of 2023.